Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 2 (2021)
Review Article
Submitted: 2021-01-26
Accepted: 2021-02-22
Published online: 2021-04-02
View PDF Download PDF file
Get Citation

Botulinum toxin type-A preparations are not the same medications — basic science (Part 1)

Halina Car1, Andrzej Bogucki2, Marcin Bonikowski3, Małgorzata Dec-Ćwiek4, Artur Drużdż5, Dariusz Koziorowski6, Monika Rudzińska-Bar7, Iwona Sarzyńska-Długosz8, Jarosław Sławek9
DOI: 10.5603/PJNNS.a2021.0027
·
Pubmed: 33797747
·
Neurol Neurochir Pol 2021;55(2):133-140.
Affiliations
  1. Deprtment of Experimental Pharmacology, Medical University of Bialystok, Poland
  2. Department of Extrapyramidal Disorders, Medical University of Łódź, Poland
  3. Neuro Rehabilitation Department, Movement Analysis Lab., Mazovian Neuropsychiatry Center, Limited Liability Company, Zagórze, Poland
  4. Department of Neurology, Collegium Medicum, Jagiellonian University, Kraków, Poland
  5. Department of Neurology, Municipal Hospital in Poznań, Poland
  6. Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warszawa, Poland
  7. Department of Neurology, Faculty of Medicine and Health Sciences. Andrzej Frycz Modrzewski Krakow University, Kraków, Poland
  8. Second Department of Neurology, Neurorehabilitation Ward, Institute of Psychiatry and Neurology, Warsaw, Poland
  9. Medical University of Gdansk, Poland, Gdansk, Poland

open access

Vol 55, No 2 (2021)
REVIEW ARTICLES — LEADING TOPIC
Submitted: 2021-01-26
Accepted: 2021-02-22
Published online: 2021-04-02

Abstract

Botulinum neurotoxin type A (BoNT/A) formulations are widely used in clinical practice. Although they share a common mechanism of action resulting in presynaptic block in acetylocholine release, their structure and pharmacological properties demonstrate some similarities and many differences. Bioequivalence has been discussed since the onset of the clinical use of BoNT/A. In this review, we provide an update on the studies and compare the molecular structure, mechanisms of action, diffusion and spread, as well as immunogenicity and dose equivalence of onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA.

Abstract

Botulinum neurotoxin type A (BoNT/A) formulations are widely used in clinical practice. Although they share a common mechanism of action resulting in presynaptic block in acetylocholine release, their structure and pharmacological properties demonstrate some similarities and many differences. Bioequivalence has been discussed since the onset of the clinical use of BoNT/A. In this review, we provide an update on the studies and compare the molecular structure, mechanisms of action, diffusion and spread, as well as immunogenicity and dose equivalence of onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

botulinum toxin A formulation, pharmacological similarities and differencies, abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA

About this article
Title

Botulinum toxin type-A preparations are not the same medications — basic science (Part 1)

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 2 (2021)

Article type

Review Article

Pages

133-140

Published online

2021-04-02

Page views

2667

Article views/downloads

4985

DOI

10.5603/PJNNS.a2021.0027

Pubmed

33797747

Bibliographic record

Neurol Neurochir Pol 2021;55(2):133-140.

Keywords

botulinum toxin A formulation
pharmacological similarities and differencies
abobotulinumtoxinA
onabotulinumtoxinA
incobotulinumtoxinA

Authors

Halina Car
Andrzej Bogucki
Marcin Bonikowski
Małgorzata Dec-Ćwiek
Artur Drużdż
Dariusz Koziorowski
Monika Rudzińska-Bar
Iwona Sarzyńska-Długosz
Jarosław Sławek

References (83)
  1. Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon. 2001; 39(11): 1703–1722.
    CrossRefPubMed
  2. Frevert J. Xeomin: an innovative new botulinum toxin type A. Eur J Neurol. 2009; 16 Suppl 2: 11–13.
    CrossRefPubMed
  3. Frevert J, Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015; 15(1): 1–9.
    CrossRefPubMed
  4. Pickett A. Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology. Clinical Applications of Botulinum Neurotoxin. 2014: 7–49.
    CrossRef
  5. WAGMAN J, BATEMAN JB. Botulinum type A toxin: properties of a toxic dissociation product. Arch Biochem Biophys. 1953; 45(2): 375–383.
    CrossRefPubMed
  6. Cai S, Sarkar HK, Singh BR. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry. 1999; 38(21): 6903–6910.
    CrossRefPubMed
  7. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010; 4: 325–332.
    CrossRefPubMed
  8. Eisele KH, Fink K, Vey M, et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011; 57(4): 555–565.
    CrossRefPubMed
  9. Frevert J, Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010; 10(2): 67–73.
    CrossRefPubMed
  10. Dressler D, Adib Saberi F, Bigalke H. Botulinum toxin therapy: reduction of injection site pain by pH normalisation. J Neural Transm (Vienna). 2016; 123(5): 527–531.
    CrossRefPubMed
  11. Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017; 69(2): 200–235.
    CrossRefPubMed
  12. Jhang JF, Kuo HC. Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. Toxins (Basel). 2016; 8(4): 120.
    CrossRefPubMed
  13. Mahrhold S, Bergström T, Stern D, et al. Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1. Biochem J. 2016; 473(17): 2645–2654.
    CrossRefPubMed
  14. Lacy DB, Tepp W, Cohen AC, et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998; 5(10): 898–902.
    CrossRefPubMed
  15. Lauc G, Pezer M, Rudan I, et al. Mechanisms of disease: The human N-glycome. Biochim Biophys Acta. 2016; 1860(8): 1574–1582.
    CrossRefPubMed
  16. Kroken AR, Blum FC, Zuverink M, et al. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons. Infect Immun. 2017; 85(1).
    CrossRefPubMed
  17. Kammerer RA, Benoit RM. Botulinum neurotoxins: new questions arising from structural biology. Trends Biochem Sci. 2014; 39(11): 517–526.
    CrossRefPubMed
  18. Sugawara Yo, Matsumura T, Takegahara Y, et al. Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol. 2010; 189(4): 691–700.
    CrossRefPubMed
  19. Lee K, Zhong X, Gu S, et al. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science. 2014; 344(6190): 1405–1410.
    CrossRefPubMed
  20. Jacky BPS, Garay PE, Dupuy J, et al. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog. 2013; 9(5): e1003369.
    CrossRefPubMed
  21. Li X, Coffield JA. Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A. PLoS One. 2016; 11(1): e0143024.
    CrossRefPubMed
  22. Sugawara Yo, Yutani M, Amatsu S, et al. Functional dissection of the Clostridium botulinum type B hemagglutinin complex: identification of the carbohydrate and E-cadherin binding sites. PLoS One. 2014; 9(10): e111170.
    CrossRefPubMed
  23. Grando SA, Zachary CB. The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol. 2018; 178(5): 1011–1019.
    CrossRefPubMed
  24. Kim YJ, Kim JH, Lee KJ, et al. Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages. PLoS One. 2015; 10(4): e0120840.
    CrossRefPubMed
  25. Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 2004; 45(7): 987–993.
    CrossRefPubMed
  26. Collins VM, Daly DM, Liaskos M, et al. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int. 2013; 112(7): 1018–1026.
    CrossRefPubMed
  27. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005; 174(3): 977–82; discussion 982.
    CrossRefPubMed
  28. Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006; 175(3 Pt 1): 1138–1142.
    CrossRefPubMed
  29. Peng CH, Jhang JF, Shie JH, et al. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistochemistry analysis. Urology. 2013; 82(6): 1452.e1–1452.e6.
    CrossRefPubMed
  30. Akaike N. Shin MC Wakita M Torii Y Harakawa T Ginnaga A Kato K Kaji R Kozaki S. Trans synaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013; 15: 1031–1043.
  31. Makunts T, Wollmer MA, Abagyan R. Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Sci Rep. 2020; 10(1): 12851.
    CrossRefPubMed
  32. Zamanian A, Ghanbari Jolfaei A, Mehran G, et al. Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression. Iran J Public Health. 2017; 46(7): 982–984.
    PubMed
  33. Brin MF, Durgam S, Lum A, et al. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol. 2020; 35(1): 19–28.
    CrossRefPubMed
  34. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008; 7(1): 50–54.
    CrossRefPubMed
  35. Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008; 10(3): 181–183.
    CrossRefPubMed
  36. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006; 13 Suppl 4: 10–19.
    CrossRefPubMed
  37. Dysport® (abobotulinumtoxinA) [prescribing information]. Boulogne-Billancourt: IpsenBiopharm Ltd; 2012. Accessed October. ; 8: 2020.
  38. Coté TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005; 53(3): 407–415.
    CrossRefPubMed
  39. Food and Drug Administration. Letter Re: Docket No FDA-2008-P-0061. April 30, 2009. Silver Spring, MD: US Food and Drug Administration; 2009. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM143989.pdf. Accessed October. ; 8: 2020.
  40. Ramirez-Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013; 28(13): 1775–1783.
    CrossRefPubMed
  41. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015; 95(1-2): 65–69.
    CrossRefPubMed
  42. Kutschenko A, Manig A, Reinert MC, et al. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA. Neurosci Lett. 2016; 627: 216–221.
    CrossRefPubMed
  43. Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007; 33(1 Spec No.): S37–S43.
    CrossRefPubMed
  44. Kerscher M, Roll S, Becker A, et al. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012; 304(2): 155–161.
    CrossRefPubMed
  45. Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008; 34(1): 52–59.
    CrossRefPubMed
  46. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010; 36 Suppl 4: 2146–2154.
    CrossRefPubMed
  47. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009; 40(3): 374–380.
    CrossRefPubMed
  48. Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2012; 2.
    CrossRefPubMed
  49. Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992; 55(9): 844–845.
    CrossRefPubMed
  50. Caleo M, Spinelli M, Colosimo F, et al. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons. J Neurosci. 2018; 38(48): 10329–10337.
    CrossRefPubMed
  51. Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008; 28(14): 3689–3696.
    CrossRefPubMed
  52. Restani L, Antonucci F, Gianfranceschi L, et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci. 2011; 31(44): 15650–15659.
    CrossRefPubMed
  53. Restani L, Novelli E, Bottari D, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic. 2012; 13(8): 1083–1089.
    CrossRefPubMed
  54. Wang T, Martin S, Papadopulos A, et al. Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a. J Neurosci. 2015; 35(15): 6179–6194.
    CrossRefPubMed
  55. Maday S, Holzbaur ELF. Autophagosome assembly and cargo capture in the distal axon. Autophagy. 2012; 8(5): 858–860.
    CrossRefPubMed
  56. Harper CB, Martin S, Nguyen TH, et al. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 2011; 286(41): 35966–35976.
    CrossRefPubMed
  57. Restani L, Giribaldi F, Manich M, et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012; 8(12): e1003087.
    CrossRefPubMed
  58. Barbanti P, Ferroni P. Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. J Pain Res. 2017; 10: 2319–2329.
    CrossRefPubMed
  59. Simpson L. The life history of a botulinum toxin molecule. Toxicon. 2013; 68: 40–59.
    CrossRefPubMed
  60. Joshi SG, Elias M, Singh A, et al. Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Neuroscience. 2011; 179: 208–222.
    CrossRefPubMed
  61. Chen F, Kuziemko GM, Amersdorfer P, et al. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997; 65(5): 1626–1630.
    CrossRefPubMed
  62. BOTOX® (onabotulinumtoxinA) [prescribing information]. Irvine, CA: Allergan, Inc.; 2013. , Accessed October. ; 8: 2020.
  63. Brin MF, Comella CL, Jankovic J, et al. CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008; 23(10): 1353–1360.
    CrossRefPubMed
  64. FDA Approval Package for Xeomin® (incobotulinumtoxinA) Injection. vol Application Number 125360 [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s0000TOC.cfm. Accessed October. 2010; 8: 2020.
  65. Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res. 2016; 29(1): 105–117.
    CrossRefPubMed
  66. Wissel J, Bensmail D, Ferreira JJ, et al. TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88(14): 1321–1328.
    CrossRefPubMed
  67. Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013; 67: 141–152.
    CrossRefPubMed
  68. Jost WH, Benecke R, Hauschke D, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9: 1913–1926.
    CrossRefPubMed
  69. Schantz E, Johnson E. Dose standardisation of botulinum toxin. The Lancet. 1990; 335(8686): 421.
    CrossRef
  70. Sesardic T. Bioassays for evaluation of medical products derived from bacterial toxins. Curr Opin Microbiol. 2012; 15(3): 310–316.
    CrossRefPubMed
  71. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol. 2009; 32(1): 28–31.
    CrossRefPubMed
  72. Panjwani N, O'Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J. 2008; 1(1): 153.
    CrossRef
  73. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay. J Neural Transm (Vienna). 2012; 119(1): 13–15.
    CrossRefPubMed
  74. Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003; 31(4): 265–276.
    CrossRefPubMed
  75. Dashtipour K, Pedouim F. Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile. Semin Neurol. 2016; 36(1): 29–33.
    CrossRefPubMed
  76. Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016; 8(3).
    CrossRefPubMed
  77. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006; 13 Suppl 1: 2–10.
    CrossRefPubMed
  78. Brown M, Nicholson G, Ardila MC, et al. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J Neural Transm (Vienna). 2013; 120(2): 291–298.
    CrossRefPubMed
  79. Hunt T, Clarke K, Rupp D, et al. IncobotulinumtoxinA drug product demonstrates lower potency when compared to onabotulinumtoxinA drug product with concurrent lower light-chain activity and atypical substrate cleavage. Toxicon. 2013; 68: 114.
    CrossRef
  80. Ferrari A, Manca M, Tugnoli V, et al. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018; 33(1): 7–18.
    CrossRefPubMed
  81. Field M, Splevins A, Picaut P, et al. AbobotulinumtoxinA (Dysport), OnabotulinumtoxinA (Botox), and IncobotulinumtoxinA (Xeomin) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel). 2018; 10(12).
    CrossRefPubMed
  82. Allergan, Ltd. BOTOX® 100 U. Summary of product characteristics [webpage on the Internet]. Surrey, UK: Datapharm Communications Ltd; 2013 [updated December 12, 2012]. Available from: http://www.medicines.org.uk/emc/medicine/112. Accessed October. ; 8: 2020.
  83. BOTOX® (onabotulinumtoxinA) [prescribing information]. Buenos Aires, Argentina: Allergan, Inc. ; 2011.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl